The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 23, 2025
Filed:
Jan. 19, 2021
Applicants:
City of Hope, Duarte, CA (US);
The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);
Inventors:
Christine E. Brown, Duarte, CA (US);
Lawrence Stern, Duarte, CA (US);
Xin Yang, Duarte, CA (US);
K. Christopher Garcia, Duarte, CA (US);
Ignacio Moraga Gonzalez, Duarte, CA (US);
Assignees:
City of Hope, Duarte, CA (US);
The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/4217 (2025.01); A61P 35/00 (2018.01); C12N 15/86 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05);
Abstract
Chimeric antigen receptor molecules that include a variant IL-13. The variant IL-13 are more selective for IL13Rα2 than IL13Rα1 by virtue of weaker binding to IL13Rα1. The chimeric antigen receptors can be used to treat IL13Rα2 expressing cancers.